Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy

Despite several therapeutic advances, patients with multiple myeloma (MM) require additional treatment options since no curative therapy exists yet. In search of a novel therapeutic antibody, we previously applied phage display with myeloma cell screening and developed TP15, a single-chain fragment...

Descripción completa

Detalles Bibliográficos
Autores principales: Klausz, Katja, Cieker, Michael, Kellner, Christian, Rösner, Thies, Otte, Anna, Krohn, Steffen, Lux, Anja, Nimmerjahn, Falk, Valerius, Thomas, Gramatzki, Martin, Peipp, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252953/
https://www.ncbi.nlm.nih.gov/pubmed/32499243
http://dx.doi.org/10.3324/haematol.2020.251371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252953/
https://www.ncbi.nlm.nih.gov/pubmed/32499243
http://dx.doi.org/10.3324/haematol.2020.251371

Ejemplares similares